O'Neill B P, Wang C H, O'Fallon J R, Colgan J D, Earle J D, Krigel R L, Brown L D, McGinnis W L
Department of Neurology, Mayo Clinic/Foundation, Rochester, MN 55905, USA.
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):559-63. doi: 10.1016/s0360-3016(98)00450-7.
We herein report updated survival and toxicity data on the entire cohort of 53 eligible patients treated on North Central Cancer Treatment Group (NCCTG) protocol 86-72-52, which is now closed.
An initial report was published in this journal in 1995. No substantive changes in the conclusions of that report were identified in this analysis. Median survival was 9.6 months for the entire cohort; median survival for the 20 patients who completed the prescribed protocol treatment was 20.7 months. The hematologic and non-hematologic toxicity distributions are virtually the same as those reported in the original paper.
Results are given for the entire group and for subsets defined by age < or = 60 versus > 60 years, and < 70 versus > or = 70 years of age.
No significant differences were observed in any of the outcome variables by age group. There was, however, a nonsignificant suggestion of poorer outcome in those who were > 60 years of age.
我们在此报告了按照北中部癌症治疗组（NCCTG）86 - 72 - 52方案接受治疗的53例符合条件患者的最新生存和毒性数据，该方案现已结束。
1995年在本期刊发表了初步报告。本次分析未发现该报告结论有实质性变化。整个队列的中位生存期为9.6个月；完成规定方案治疗的20例患者的中位生存期为20.7个月。血液学和非血液学毒性分布与原始论文报道的基本相同。
给出了整个组以及按年龄≤60岁与＞60岁、＜70岁与≥70岁定义的亚组的结果。
各年龄组在任何结局变量上均未观察到显著差异。然而，60岁以上患者的结局有较差的非显著趋势。
